Big Pharma Vaccine Trials Drop 27%: Shift to Key Projects & Combination Vaccines

Vaccine Development Shifts Focus to Combination Products and Late-Stage Trials

Clinical vaccine pipelines among major global pharmaceutical companies have contracted by nearly 27% in the past year, according to a new report. However, this reduction isn’t indicative of a slowdown in vaccine innovation, but rather a strategic realignment towards projects closer to commercialization and higher-value areas like combination vaccines.

The report, published by the Korea Biopharmaceutical Association on February 18, 2026, analyzed the clinical pipelines of six leading vaccine developers: Pfizer, Sanofi, MSD, GSK, Moderna, and AstraZeneca. The total number of vaccine candidates in clinical development across these companies decreased from 75 in the previous year to 55 currently.

This decline was most pronounced in the early stages of development. Phase 1 clinical trials decreased from 25 to 18, and Phase 2 trials fell from 34 to 22. Phase 3 trials experienced a more modest reduction, decreasing by only one, from 16 to 15. This suggests a deliberate shift in resource allocation towards projects with a higher probability of success and quicker paths to market.

The association’s analysis indicates a “selective entry of new candidate substances,” and a clear “strategy of focusing resources on tasks with a high probability of success.” This approach reflects the inherent risks and high costs associated with pharmaceutical research and development.

Sanofi currently holds the largest number of vaccine candidates in clinical development among the companies surveyed, with 15 projects (6 in Phase 1, 5 in Phase 2, and 4 in Phase 3). MSD, conversely, is operating a comparatively limited clinical vaccine portfolio, maintaining only one project in Phase 3.

Across all six companies, 22 vaccine candidates are currently in Phase 2 clinical trials, followed by 18 in Phase 1 and 15 in Phase 3. This distribution further supports the trend of prioritizing later-stage development.

The focus of vaccine development remains centered on respiratory infectious diseases, including influenza, COVID-19, and respiratory syncytial virus (RSV). Notably, there’s a growing emphasis on developing combination vaccines targeting multiple respiratory pathogens. Examples include vaccines combining protection against COVID-19 and influenza, and those targeting RSV and human metapneumovirus (hMPV).

The development of these combination vaccines is driven by several factors. They offer the potential to address seasonal epidemics and simultaneous infections more effectively, and they can increase the convenience of vaccination for individuals, potentially improving uptake rates.

The broader trend reflects a shift in the global pharmaceutical industry’s vaccine strategy. Rather than simply expanding the number of vaccine candidates in development, companies are now prioritizing a more focused approach, concentrating resources on projects with the greatest potential for clinical and commercial success. While the overall pipeline has decreased, the competitiveness in high-value-added areas, such as combination vaccines, has demonstrably strengthened.

This strategic realignment is occurring against a backdrop of increasing vaccine innovation, particularly with the emergence of new technologies like RNA vaccines. As reported by researchers, the field is on the cusp of a “groundbreaking renaissance,” propelled by scientific and technological breakthroughs. However, challenges remain, including low vaccine uptake in some populations and operational hurdles related to delivery and administration.

The World Health Organization (WHO) continues to emphasize the power of vaccines, designating the last week of April as “World Immunization Week” to promote their benefits. Since 1974, vaccines have saved an estimated 154 million lives worldwide and reduced infant deaths by 40%. The value of the vaccine market has increased by 15% annually over the last five years, demonstrating the continued importance of vaccine development and accessibility.